University of Patras is a university established in 1964 in Patras, Greece. Initially housed in the city centre, the university's campus is now located in the adjacent municipality of Rio. Covering an area of 4.5 km², it is one of the largest in the country. Until September 2002, it was the only university in the Peloponnese and Western Greece with the exception of Epirus.In particular it comprises 5 Schools – School of science, School of Engineering, School of Social Studies and Humanities, School of Health science and School of Business Administration. It is the third largest university in the country, with 18,500 undergraduate students, 2000 post-graduate students, 670 teaching staff, 369 administrative personnel and 403 teaching and research assistants. The initial emphasis on science and technology has been extended to other academic areas such as Health science, Humanities and Business studies. Today, its 22 departments, with a large number of sectors and consequently a great range of disciplines, reflect a balanced academic environment.The university is accessible by GR-8A, and now the new bypass with an interchange in the west and a westbound interchange in the northeast. The elevation is around 50 m above sea level. The facilities lie in the western part, the central part and the northern part. The far western part, and the eastern part are empty.The campus has 4 entrances; the Platonos Entrance Eisodos Platonos, the Dionysios Solomos Entrance Eisodos Dionysiou Solomou, lying to the west next to Papandreou Avenue which is also a road linking to Kastritsi, Georgios Seferis Entrance Eisodos Georgios Seferis in the east and G. Ritsou Entrance Eisodos G. Ritsou with the old GR-8A in the north. The mountains are situated in the southeast. The track and field and sporting grounds are in the southern part. Wikipedia.
News Article | May 19, 2017
Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers at the Helmholtz Zentrum München, in partnership with the German Center for Lung Research (DZL), have discovered a novel mechanism that causes this to happen. Their study, published in 'Nature Communications', also shows that various active substances could potentially be used to treat this condition. Malignant pulmonary effusion (MPE) frequently occurs in patients with metastatic breast or lung cancer. It involves a build-up of excess fluid in the pleural cavity, the area between the lungs and the chest wall, with accompanying malignant cells. The lung is surrounded by fluid, which can cause shortness of breath and chest pain, for example, and may even prove fatal. "There is still no effective treatment for this," explains Professor Georgios Stathopoulos, research group leader at the Institute for Lung Biology (ILBD) and Comprehensive Pneumology Center (CPC) at the Helmholtz Zentrum München. "In the case of larger pulmonary effusions with volumes exceeding one liter, treatment usually involves aspiration in order to relieve pressure on the lung." Stathopoulos and his team are working to understand the causes of pleural effusion, which remain unclear, in an effort to advance the treatment of this condition in the future. In the current study, the scientists examined cancer cells they had obtained from pleural effusions with a malignant mutation in the KRAS gene. KRAS is known to play a key role in the growth of various malignant tumors. "We were able to show that these cells release a messenger substance into the bloodstream, which in turn attracts immune cells.* These cells then wander via the spleen to the pleural cavity, where they cause the effusion," Stathopoulos says, explaining the mechanism. In addition, the scientists found the KRAS-mutant cancer cells in the MPE material of lung cancer patients as well as in the cell lines derived from them. In order to verify whether their newly acquired knowledge could be applied in clinical practice, the researchers tested two active substances that interrupt the mechanism at two different points. In an experimental model they were able to demonstrate that both the KRAS inhibitor Deltarasin** and an antibody against the messenger substance released by the cancer cells prevented pleural effusion. "Nearly two thirds of all MPEs are the result of lung cancer. In view of the still large numbers of smokers, appropriate treatments are urgently needed," Stathopoulos stresses. "Our results lead us to assume that drugs that target the mechanism we have discovered could be a potential treatment option. Further studies are now needed to confirm that." Lung cancer expert Georgios Stathopoulos joined the Helmholtz Zentrum München in 2015. He also heads a working group at the Laboratory for Molecular Respiratory Carcinogenesis at the University of Patras in Greece. The study that has now been published was the outcome of collaboration between the two working groups. * The messenger substance in question is CCL2 (CC-Chemokinligand 2), which is often released when inflammation occurs. ** Deltarasin prevents the transport of the cancer-causing protein KRAS to the cell membrane. In 2015 a team headed by Professor Stathopoulos discovered that in lung cancer patients mast cells collect in the pleural cavity, where they cause a pleural effusion. In a preclinical model, initial experiments with Imatinib, a tyrosine kinase inhibitor, revealed a smaller pleural effusion and fewer mast cells. The co-authors of the study, Malamati Vreka and Mario Pepe, are PhD students at the CPC Research School and participants in the PhD training program at the Helmholtz Graduate School of Environmental Health, in short HELENA. The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www. The Comprehensive Pneumology Center (CPC) is a joint research project of the Helmholtz Zentrum München, the Ludwig-Maximilians-Universität Clinic Complex and the Asklepios Fachkliniken München-Gauting. The CPC's objective is to conduct research on chronic lung diseases in order to develop new diagnosis and therapy strategies. The CPC maintains a focus on experimental pneumology with the investigation of cellular, molecular and immunological mechanisms involved in lung diseases. The CPC is a site of the Deutsches Zentrum für Lungenforschung (DZL). http://www. The German Center for Lung Research (DZL) pools German expertise in the field of pulmonology research and clinical pulmonology. The association's head office is in Giessen. The aim of the DZL is to find answers to open questions in research into lung diseases by adopting an innovative, integrated approach and thus to make a sizeable contribution to improving the prevention, diagnosis and individualized treatment of lung disease and to ensure optimum patient care. http://www.
Sotiropoulou G.,University of Patras |
Pampalakis G.,University of Patras
Trends in Pharmacological Sciences | Year: 2012
Kallikrein-related peptidases (KLKs) constitute a family of 15 serine proteases. Recent studies have shed light on key physiological functions of KLK enzymes and implicate their deregulation in major human pathologies such as neurodegenerative and inflammatory diseases, skin conditions, asthma, and cancer. Consequently, KLKs have emerged as novel targets for pharmacological intervention. Given the pleiotropic roles of KLKs, both activators and inhibitors of KLK activities are of therapeutic interest. For example, inhibitors of hyperactive KLKs in the epidermis would be effective against excess skin desquamation and inflammation, whereas KLK activators could benefit hyperkeratosis caused by diminished KLK proteolysis. Expression of active KLKs by cancer cells and tissues can be exploited to target prodrugs that are proteolytically cleaved to release a cytotoxic compound or a cytolytic toxin at the site of KLK protease activity. Here, we review current approaches for the design and testing of KLK-based therapeutics. © 2012 Elsevier Ltd.
Papatheodoropoulos C.,University of Patras
BMC Neuroscience | Year: 2015
Background: Elucidating specializations of the intrinsic neuronal network between the dorsal and the ventral hippocampus is a recently emerging area of research that is expected to help us understand the mechanisms underlying large scale functional diversification along the hippocampus. The aim of this study was to characterize spontaneous network activity between the dorsal and the ventral hippocampus induced under conditions of partial or complete blockade of GABAergic inhibition (i.e. disinhibition). Results: Using field recordings from the CA3 and CA1 fields of hippocampal slices from adult rats I found that ventral compared with dorsal hippocampus slices displayed higher propensity for and higher frequency of occurrence of spontaneous field potentials (spfps) at every level of disinhibition. Also NMDA receptor-depended spfps (spfps-nmda) occurred with higher probability more frequently and were larger in the ventral compared with the dorsal hippocampus. Importantly, blockade of GABAB receptors produced a stronger effect in enhancing the probability of generation of spfps and spfps-nmda in the dorsal compared with the ventral hippocampal slices and increased spfps-nmda only in dorsal slices. Conclusion: These results demonstrate a higher intrinsic neuronal excitability of the ventral compared with the dorsal local circuitry with the considerable contribution of NMDA receptors. Furthermore, the GABAB receptors control the total and the NMDA receptor-dependent excitation much less effectively in the ventral part of the hippocampus. It is proposed that NMDA and GABAB receptors significantly contribute to differentiate local network dynamics between the dorsal and the ventral hippocampus with important implications in the information processing performed along the long hippocampal axis. © 2015 Papatheodoropoulos.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.4-1 | Award Amount: 11.55M | Year: 2013
The target of the Smartonics project is the development of Pilot lines that will combine smart technologies with smart nanomaterials for the precision synthesis of Organic Electronic (OE) devices. The Smartonics objectives are: 1.Development of smart Nanomaterials for OEs (polymer & small molecule films, plasmonic NPs and super-barriers) by process and computational modeling optimization. 2.Development of smart Technologies (r2r printing and OVPD machines combined with precision sensing & laser tools and processes). 3.Integration of Nanomaterials & Technologies in Pilot lines for precision synthesis of Nanomaterials & OE devices, optimization, demonstration and evaluation for Industrial applications. Smartonics will develop three Pilot lines: a) OVPD Pilot line equipped with in-line optical sensing tools, b) r2r printing Pilot line, which will combine optical sensing and laser processing tools, and c) s2s Pilot line for the precision fabrication of OE devices (e.g. OLEDs, sensors from state-of-the-art Nanomaterials) and for the evaluation of encapsulation of these devices. The above will be up-scaled in Industrial processes. More specifically: - The parameters for small molecule OPVs will be up-scaled to Industrial scale OVPD machine. - The process parameters for r2r OPVs will be up-scaled and demonstrated in r2r printing machines. - The advances and precision in the synthesis of nanomaterials by the optical sensing tool will be evaluated for flexible displays. - The advances for the r2r printing process will be evaluated for large-scale production of OPVs. - The flexible OPVs will be validated and implemented in automotives applications. All the above are consistent with the topic NMP.2012.1.4-1 since the the targets of project are including the development of Pilot lines that will be combined with production machines (gas (transport and printing), precision and fabrication tools and processes for the precision synthesis of Nanomaterials and OEs.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: FI.ICT-2011.1.8 | Award Amount: 17.36M | Year: 2013
FI-STAR will establish early trials in the Health Care domain building on Future Internet (FI) technology leveraging on the outcomes of FI-PPP Phase 1. It will become self-sufficient after the end of the project and will continue on a sustainable business model by several partners. In order to meet the requirements of a global Health industry FI-STAR will use a fundamentally different, reverse cloud approach that is; it will bring the software to the data, rather than bringing the data to the software. FI-STAR will create a robust framework based of the software to data paradigm. A sustainable value chain following the life cycle of the Generic Enablers (GEs) will enable FI-STAR to grow beyond the lifetime of the project. FI-STAR will build a vertical community in order to create a sustainable ecosystem for all user groups in the global Health care and adjacent markets based on FI-PPP specifications. FI-STAR will deploy and execute 7 early trials across Europe, serving more than 4 million people. Through the trials FI-STAR will validate the FI-PPP core platform concept by using GEs to build its framework and will introduce ultra-light interactive applications for user functionality. It will pro-actively engage with the FI-PPP to propose specifications and standards.FI-STAR will use the latest digital media technology for community building and will proactively prepare for Phase 3 through targeted elicitation of new partners using open calls. Finally, FI-STAR will collaborate with other FI-PPP projects, through the mechanisms in place, by actively interacting with all necessary bodies. FI-STAR is a unique opportunity for implementing Future Internet Private-Public Partnership in the Health Care domain, by offering to the community standardised and certified software including a safe, secure and resilient platform, taking advantage of all Cloud Computing benefits and guaranteeing the protection of sensitive and personal data travelling in Public Clouds.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: FoF.NMP.2013-2 | Award Amount: 9.65M | Year: 2013
The young optoelectronic industry has critical mass and already impacts for more than the 10% on the European economy, employing 290 000 people and guarantees a stable double digit growth in current and coming years. Europe is playing a leading role in R&D (>1,000 research organization active) and is still able to face Far East and American competitors in manufacturing. whiteR is a necessary action to translate this R&D excellence into future leadership in manufacturing high value added optoelectronic devices. whiteR production island aims to make a move away from the manual assembly processes that have characterized the industry for decades to high-accuracy, high-yield, automated methods. The new manufacturing concept is based on the combination of fully automated, self contained, white room modules whose components - robots, end effectors, transport, handling and tooling systems - are conceived as Plug&Produce mechatronic sub-modules properly configured coherently with the production requirements. The technical objectives of whiteR system are: 50% reduction of cost compared to current productions system; 30% set-up and ramp-up time reduction by self adaptive reconfigurability; All components of the production system reusable re-assembled and upgraded in a new different system; Creation of a EU/International standard for optoelectronic package configuration. The achievement of the objectives will be demonstrated by 2 different demonstrators where the same whiteR island will be reconfigured to be used in two different real industrial environments related to the laser processing (Prima Power) and the solar energy systems (NSL). whiteR team forms a lean and efficient organization linking together 3 academic and research institutions to 10 industrial partners from 5 different countries, including both system development companies and industrial end users.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: FoF.NMP.2013-7 | Award Amount: 10.67M | Year: 2013
LIAA aims to keep assembly jobs in Europe by creating and implementing a framework that enables humans and robots to truly to work together in assembly tasks. Co-working allows the senses and intelligence of the human to be complemented by the strength and endurance of the automation and so obtains the best from each of them, reducing repetitive injuries and costs and enhancing job satisfaction and the average length of time that a worker can continue in the same job. The LIAA framework will be developed not from theory, but instead from the extensive experience partners have gained through many previous projects. It will not be a thought experiment, but applied to create solutions to five real use cases from five different areas of industrial assembly. In this way the framework will be forced not only to be useable and functional but also general enough to be broadly applicable. A LIAA work station c an be used either by human or robot alone or by both together, and the instructions for tasks will be written for both, by formalising a modular skill hierarchy and creating both human and machine instruction sets for each skill. People will be able to keep track of what the automation is doing and is about to do via an augmented reality (AR) display. The robot will keep track of what the human is doing and is about to do via a dedicated camera-based system and some intelligent prediction algorithms. To date, safety regulations only cover very limited types of human-robot interaction in industry. The inclusion of Denmarks Notified Body as a partner in LIAA ensures that not only will all our solutions be properly risk assessed for actual use in industry but also that our experiences will feed back to those responsible for drafting new EU robot co-worker safety regulations. The direct final outcome of LIAA will be five working co-worker solutions to diverse industrial assembly use cases and a strong unifying framework providing a basis for future co-worker solutions.
Lianos P.,University of Patras
Journal of Hazardous Materials | Year: 2011
The present review aims to give to a researcher who has no experience with Photofuelcells all necessary basic knowledge to join the field without much trouble and to give to an experienced researcher a handy manual of reference. The author has dealt with the principal matters related with the design of a photoelectrochemical cell and the factors that affect efficient production of electricity by photocatalytic degradation of (principally) organic and (secondarily) inorganic waste materials. A large portion of the paper is devoted to the review of materials used for making a photoanode since most of the accomplished research is on this exact matter. The paper also briefly reviews the materials used to make the rest of the components of the cell as well as the models of cell efficiency and photodegradation procedures during cell operation. © 2010 Elsevier B.V.
Papadakos, University of Patras and Mourjopoulos | Date: 2016-06-08
A novel method for generating sufficient electric power for energy harvesting applications from acoustic power produced within enclosures and especially by operating loudspeakers is disclosed. The disclosed method is applied in conjunction with piezoelectric transducers, which interact with acoustic waves via an acoustical-mechanical coupling mechanism. The coupling mechanism disclosed herein offers a mechanical advantage and achieves impedance matching between air and the piezoelectric material. This mechanism achieves the optimal energy transfer and the generation of sufficient electric power for energy harvesting applications.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2013.5.2 | Award Amount: 4.18M | Year: 2014
NoTremor aims to provide patient specific computational models of the coupled brain and neuromuscular systems that will be subsequently used to improve the quality of analysis, prediction and progression of Parkinsons disease. In particular, it aspires to establish the neglected link between brain modelling and neuromuscular systems that will result in a holistic representation of the physiology for PD patients. A significant breakthrough of NoTremor is that these models will not be used for abstract representation of the physiology or as a match between theory and clinical measurements. On the contrary, they will be used with a totally new perspective; predictive simulation. NoTremor will integrate computational models of the basal ganglia and brainstem into a unique multi-scale parametric computational model that can be subsequently simulated in the NoTremor simulation engine in a physics-based manner. NoTremor will revolutionize research in the pathophysiology of neurodegenerative movement disorders and provide a novel approach for their analysis founded on a solid computational modelling basis that links midbrain degenerations to motor behaviour. The computational models will be quantified and validated through test campaigns with a very large cohort of PD patients. The impact of such a groundbreaking approach is huge and the foundations laid here are expected to result in a widespread adoption of predictive simulation not only in PD, but also in other neurodegenerative diseases. The ultimate challenging use of the NoTremor developments will be from the one side clinical decision support and from the other side the investigation, virtual prototyping and testing of new drugs using virtual patient models. UCB Pharma aims to incorporate the NoTremor computational modelling and simulation approach in their drug development pipeline that is expected to significantly boost the efficiency and personalization of new drugs.